title: Haematological safety of long-term therapy with linezolid.
authors.forename: Silvia
authors.initials: S
authors.lastname: Garazzino
authors.forename: Francesco Giuseppe
authors.initials: FG
authors.lastname: De Rosa
authors.forename: Olivia
authors.initials: O
authors.lastname: Bargiacchi
authors.forename: Sabrina
authors.initials: S
authors.lastname: Audagnotto
authors.forename: Agostino
authors.initials: A
authors.lastname: Maiello
authors.forename: Giovanni
authors.initials: G
authors.lastname: Di Perri
mesh_terms: D000081:Acetamides / Q000009:adverse effects* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000009:adverse effects* / Q000627:therapeutic use; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced*; D006801:Humans; D000069349:Linezolid; D008297:Male; D016106:Methicillin Resistance; D008875:Middle Aged; D023303:Oxazolidinones / Q000009:adverse effects* / Q000627:therapeutic use; D011446:Prospective Studies; D012293:Rifampin / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D000081:Acetamides; D000890:Anti-Infective Agents; D023303:Oxazolidinones; D000069349:Linezolid; D012293:Rifampin